Stockreport

NewAmsterdam Pharma: Cholesterol-Lowering Player Is A Risk-On Buy Today [Seeking Alpha]

NewAmsterdam Pharma Company N.V. - Ordinary Shares  (NAMS) 
PDF Obicetrapib met primary and secondary endpoints in three Phase 3 trials, with significant LDL-C reductions and favorable safety, supporting regulatory filings in Europe [Read more]